The Bronchopulmonary Dysplasia drugs in development market research report provides comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Bronchopulmonary Dysplasia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued products.
GlobalData tracks 17 drugs in development for Bronchopulmonary Dysplasia by 16 companies/universities/institutes. The top development phase for Bronchopulmonary Dysplasia is preclinical with seven drugs in that stage. The Bronchopulmonary Dysplasia pipeline has 16 drugs in development by companies and one by universities/ institutes. Some of the companies in the Bronchopulmonary Dysplasia pipeline products market are: Velvio, Oak Hill Bio and Alveolus Bio.
The key targets in the Bronchopulmonary Dysplasia pipeline products market include Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA), Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG), and Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB).
The key mechanisms of action in the Bronchopulmonary Dysplasia pipeline product include Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) Agonist with three drugs in Phase II. The Bronchopulmonary Dysplasia pipeline products include six routes of administration with the top ROA being Inhalational and five key molecule types in the Bronchopulmonary Dysplasia pipeline products market including Small Molecule, and Cell Therapy.
Bronchopulmonary Dysplasia overview
Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease that develops in preterm neonates treated with oxygen and positive-pressure ventilation. Symptoms of BPD include tachypnea, tachycardia, increased respiratory effort (with retractions, nasal flaring, and grunting), and bluish skin color. Risk factors include congenital heart disease and severe respiratory or lung infection; premature babies who have a low birth weight seem to be at greater risk for developing BPD. Treatment includes bronchodilators, diuretics, and antibiotics.
For a complete picture of Bronchopulmonary Dysplasia’s pipeline drug market, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
